Table 1 Demographic and clinical characteristics of maternal participants by vaccine platform.

From: Maternal immune response and placental antibody transfer after COVID-19 vaccination across trimester and platforms

 

Overall (N = 158)

Ad26.COV2.S (N = 28)

mRNA-1273 (N = 61)

BNT162b2 (N = 69)

P

Maternal age, years

34 [32, 36]

34 [32, 36]

33 [32, 36]

34 [32, 36]

0.78

Gravidity

2 [1, 3]

2 [2, 3]

2 [1, 3]

2 [1, 3]

0.27

Parity

1 [0, 1]

1 [0, 1]

1 [0, 1]

1 [0, 1]

0.73

Race (%)

 Asian

9 (6)

1 (4)

3 (5)

5 (7)

0.36

 Black or African American

4 (3)

2 (7)

1 (2)

1 (1)

 

 Other

6 (4)

3 (11)

2 (3)

1 (1)

 

 Unknown/not reported

3 (2)

1 (4)

1 (2)

1 (1)

 

 White

135 (85)

21 (75)

54 (89)

60 (87)

 

 American Indian or Alaskan native

1 (1)

0 (0)

0 (0)

1 (1)

 

Ethnicity (%)

 Hispanic

9 (6)

4 (14)

3 (5)

2 (3)

0.02

 non-Hispanic

141 (89)

20 (71)

57 (93)

64 (93)

 

 Unknown/not reported

8 (5)

4 (14)

1 (2)

3 (4)

 

Insurance status (%)

 Private

152 (96)

25 (89)

61 (100)

66 (96)

0.05

 Public

5 (3)

3 (11)

0 (0)

2 (3)

 

 Unknown

1 (1)

0 (0)

0 (0)

1 (1)

 

Pre-pregnancy BMI, kg/m2

24 [22, 27]

23 [22, 27]

23 [22, 27]

24 [22, 26]

1.00

Obesity (%)

 No

118 (75)

22 (79)

42 (69)

54 (78)

0.47

 Yes

40 (25)

6 (21)

19 (31)

15 (22)

 

Autoimmune condition (%)

 No

152 (96)

28 (100)

58 (95)

66 (96)

0.74

 Yes

6 (4)

0 (0)

3 (5)

3 (4)

 

Prior infection with SARS-CoV-2a (%)

 No

153 (97)

26 (93)

58 (95)

69 (100)

0.06

 Yes

5 (3)

2 (7)

3 (5)

0 (0)

 

Trimester of vaccination (%)

 First

18 (11)

2 (7)

7 (11)

9 (13)

0.05

 Second

88 (56)

13 (46)

42 (69)

33 (48)

 

 Third

52 (33)

13 (46)

12 (20)

27 (39)

 

Time from vaccination to sample collectionb, days

50 [27, 86]

58 [38, 85]

62 [27, 91]

42 [22, 74]

0.10

  1. BMI body mass index.
  2. aFour participants tested positive for SARS-CoV-2 prior to vaccination and one participant tested positive at delivery.
  3. bDefined time from a single dose of Ad26.COV2.S vaccine or second dose of mRNA-1273 or BNT162b2 and sample collection. Continuous variables presented as median [IQR] and categorical variables as n (%). Differences between groups assessed by Kruskal–Wallis (continuous) or Fisher’s exact test (categorical).